Intraplacental choriocarcinoma in a term pregnancy: Is serial postpartum hCG assessment necessary?

Lila Marshall; Naixin Zhang; Kyla Jorgenson; Leon Metlay; Ashlee Smith

doi:10.1016/j.gore.2023.101196

Intraplacental choriocarcinoma in a term pregnancy: Is serial postpartum hCG assessment necessary?

Gynecol Oncol Rep. 2023 Apr 29:47:101196. doi: 10.1016/j.gore.2023.101196. eCollection 2023 Jun.

Authors

Lila Marshall¹, Naixin Zhang², Kyla Jorgenson³, Leon Metlay⁴, Ashlee Smith²

Affiliations

¹ Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA.
² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA.
³ Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY USA.
⁴ Division of Gynecologic Pathology, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY, USA.

Abstract

Intraplacental choriocarcinoma (IC), or choriocarcinoma in situ, is a rare disease on the gestational trophoblastic disease (GTD) spectrum, with <100 case reports available in the literature. We propose that many patients with IC are likely to be missed as the majority of patients do not present with metastases. Currently, there are no standardized protocols in existence for postpartum monitoring of these patients. We present a case of IC identified in the term placenta of a 21-year-old who delivered by primary cesarean due to concern for fetal intolerance of labor. Subsequently, we review the recommendations available on postpartum monitoring of this likely under-diagnosed condition.

Keywords: Choriocarcinoma; Gestational trophoblastic neoplasia; Intraplacental; Trophoblastic disease.

Publication types

Case Reports